Liquidia Co. (NASDAQ:LQDA) Short Interest Up 12.1% in July

Liquidia Co. (NASDAQ:LQDA) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totalling 12,870,000 shares, an increase of 12.1% from the July 15th total of 11,480,000 shares. Based on an average daily volume of 801,600 shares, the short-interest ratio is currently 16.1 days.

Insider Activity

In other news, CFO Michael Kaseta sold 3,906 shares of the stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $12.53, for a total transaction of $48,942.18. Following the transaction, the chief financial officer now directly owns 312,389 shares in the company, valued at $3,914,234.17. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CFO Michael Kaseta sold 3,906 shares of the stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $12.53, for a total transaction of $48,942.18. Following the transaction, the chief financial officer now directly owns 312,389 shares in the company, valued at $3,914,234.17. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Roger Jeffs sold 8,053 shares of the stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $12.53, for a total transaction of $100,904.09. Following the transaction, the chief executive officer now owns 818,932 shares in the company, valued at $10,261,217.96. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,437 shares of company stock worth $268,549. Corporate insiders own 31.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Patient Square Capital LP purchased a new position in shares of Liquidia in the first quarter worth $105,942,000. Vanguard Group Inc. increased its stake in shares of Liquidia by 1.5% in the first quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock worth $42,587,000 after acquiring an additional 43,352 shares during the period. Kynam Capital Management LP increased its stake in shares of Liquidia by 34.9% in the fourth quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock worth $32,461,000 after acquiring an additional 698,324 shares during the period. Farallon Capital Management LLC acquired a new stake in shares of Liquidia in the first quarter worth $30,311,000. Finally, Vestal Point Capital LP acquired a new stake in shares of Liquidia in the fourth quarter worth $12,331,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

LQDA has been the subject of a number of analyst reports. Needham & Company LLC decreased their target price on shares of Liquidia from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. Raymond James initiated coverage on shares of Liquidia in a research report on Friday. They set an “outperform” rating and a $27.00 target price for the company. Oppenheimer initiated coverage on shares of Liquidia in a research report on Tuesday, June 25th. They set a “market perform” rating for the company. Finally, HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Liquidia in a research report on Wednesday, July 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. According to MarketBeat, Liquidia presently has an average rating of “Moderate Buy” and a consensus target price of $22.00.

Liquidia Trading Up 2.0 %

NASDAQ LQDA opened at $14.11 on Monday. The company has a fifty day simple moving average of $12.23 and a two-hundred day simple moving average of $13.35. The stock has a market cap of $1.08 billion, a P/E ratio of -9.04 and a beta of 0.32. Liquidia has a 12-month low of $5.71 and a 12-month high of $16.99.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).